The Breast
Volume 19, Issue 4 , Pages 260-267 , August 2010

Risk assessment, screening and prevention of breast cancer: A look at cost-effectiveness

  • Gail S. Lebovic

      Affiliations

    • American Society of Breast Disease, P.O. Box 1620, Frisco, TX 75034, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 877 237 4245; fax: +1 972 624 8414.
    • Dr. Lebovic is President of the American Society of Breast Disease.
    • ,
  • Alan Hollingsworth

      Affiliations

    • Mercy Women’s Center, Department of Surgery, Mercy Health Center, 4300 McAuley Blvd. Oklahoma City, OK 73120, United States
    • Tel.: +1 405 936 5455; fax: +1 405 936 5629.
    • ,
  • Stephen A. Feig

      Affiliations

    • University of California, Irvine School of Medicine, Director of Breast Imaging, UCI Medical Center, 101 The City Drive South, Route 140, Orange CA 92868-3298, United States
    • Tel.: +1 714 456 6905, fax: +1 714 456 6903.

References 

  1. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 1998;90:1371–1388
  2. Hollingsworth AB, Singletary SE, Morrow M, Francescatti DS, O'Shaughnessy JA, Hartman A-R, et al. Current comprehensive assessment and management of women at increased risk for breast cancer. Am J Surg. 2004;187:349–362
  3. Dooley WC, Ljung BM, Veronesi U, Cazzaniga M, Elledge RM, O'Shaughnessy JA, et al. Ductal lavage for detection of cellular atypia in women at high risk for breast cancer. J Natl Cancer Inst. 2001;93:1624–1632
  4. Fabian CJ, Kimler BF, Zalles CM, Klemp JR, Kamel S, Zeiger S, et al. Short-term breast cancer prediction by random periareolar fine-needle aspiration cytology and the Gail risk model. J Natl Cancer Inst. 2000;92:1217–1227
  5. Buehring GC, Letscher A, McGirr KM, Khandhar S, Che LH, Nguyen CT, et al. Presence of epithelial cells in nipple aspirate fluid is associated with subsequent breast cancer: a 25-year prospective study. Breast Cancer Res Treat. 2006;98:63–70
  6. Baltzell KA, Moghadassi M, Rice T, Sison JD, Wrensch M. Epithelial cells in nipple aspirate fluid and subsequent breast cancer risk: a historic prospective study. BMC Cancer. 2008;8:75
  7. Wrensch MR, Petrakis NL, King EB, Miike R, Mason L, Chew KL, et al. Breast cancer incidence in women with abnormal cytology in nipple aspirates of breast fluid. Am J Epidemiol. 1992;135:130–141
  8. Vogel VG, Costantino JP, Wickerham DL, Cronin WM, Cecchini RS, Atkins JN, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes. JAMA. 2006;295:2727–2741
  9. Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007;57:75–89
  10. Taneja C, Edelsberg J, Weycker D, Guo A, Oster G, Weinreb J. Cost effectiveness of breast cancer screening with contrast-enhanced MRI in high-risk women. J Am Coll Radiol. 2009;6:171–179
  11. Rosenquist CJ, Lindfors KK. Screening mammography in women aged 40–49 years: analysis of cost-effectiveness. Radiology. 1994;191:647–650
  12. Salzmann P, Kerlikowske K, Phillips K. Cost-effectiveness of screening mammography of women aged 40–49 years of age. Ann Intern Med. 1997;127:955–965
  13. Moskowitz M, Fox SH. Cost analysis of aggressive breast cancer screening. Radiology. 1979;130:253–256
  14. Moskowitz M. Costs of screening for breast cancer. Radiol Clin North Am. 1987;25:1031–1037
  15. Eddy DM. Screening for breast cancer. Ann Intern Med. 1989;111:389–399
  16. Feig SA. Mammographic screening of women aged 40–49 years: benefit, risk, and cost considerations. Cancer. 1995;76:2097–2106
  17. Tabar L, Yen M-F, Vitak B, Chen H-H, Smith RA, Duffy SW. Mammography service screening and mortality in breast cancer patients: 20-year follow-up before and after introduction of screening. Lancet. 2003;361:1405–1410
  18. Coldman A, Phillips N, Warren L, Kan L. Breast cancer mortality after screening mammography in British Columbia women. Int J Cancer. 2007 Mar;120(5):1076–1108
  19. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996;
  20. Rosenquist CJ, Lindfors KK. Screening mammography beginning at age 40 years: a reappraisal of cost-effectiveness. Cancer. 1998;82:2235–2240
  21. Tengs TO, Adams ME, Pliskin JS, Safran DG, Siegel JE, Weinstein MC, et al. Five hundred life-saving interventions and their cost-effectiveness. Risk Anal. 1995;15:369–390
  22. Brown ML. Sensitivity analysis in the cost-effectiveness of breast cancer screening. Cancer. 1992;69:1963–1967
  23. Van der Maas PJ, de Koning HJ, van Ineveld BM, van Oortmarssen GJ, Habbema JD, Lubbe KT, et al. The cost-effectiveness of breast cancer screening. Int J Cancer. 1989;43:1055–1060
  24. Feig SA. Increased benefit from shorter screening mammography intervals for women ages 40–49 years. Cancer. 1997;80:2035–2039
  25. Blanks RG, Bennett RL, Patrick J, Cush S, Davison C, Moss SM. The effect of changing from one to two views at incident (subsequent) screens in the NHS breast-screening programme in England: impact on cancer detection and recall rates. Clin Radiol. 2005;60:674–680
  26. Pisano ED, Gatsonis C, Hendrick E, Yaffe M, Baum JK, Acharyya S, et al. Diagnostic performance of digital versus film mammography for breast-cancer screening. N Engl J Med. 2005;353:1773–1783
  27. Tosteson AN, Stout NK, Fryback DG, Acharyya S, Herman BA, Hannah LG, et al. Cost-effectiveness of digital mammography in breast cancer screening. Ann Intern Med. 2008;148:1–10
  28. Cyrlak D. Induced costs of low-cost screening mammography. Radiology. 1988;168:661–663
  29. Poplack SP, Carney PA, Weiss JE, Titus-Ernstoff L, Goodrich ME, Tosteson AN, et al. Screening mammography: costs and use of screening-related services. Radiology. 2005;234:79–85
  30. Lidbrink E, Elfving J, Frisell J, Jonsson E. Neglected aspects of false positive findings of mammography in breast cancer screening: analysis of false positive cases from the Stockholm trial. BMJ. 1996;312:273–276
  31. Elmore JG, Barton MB, Moceri VM, Polk S, Arena PJ, Fletcher SW, et al. Ten-year risk of false positive screening mammograms and clinical breast examinations. N Engl J Med. 1998;338:1089–1109
  32. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer – 96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272–282
  33. Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283–290
  34. Cummings SR, Tice JA, Bauer S, Browner WS, Cuzick J, Ziv E, et al. Prevention of breast cancer in postmenopausal women: approaches to estimating and reducing risk. J Natl Cancer Inst. 2009;101:384–398

PII: S0960-9776(10)00067-6

doi: 10.1016/j.breast.2010.03.013

The Breast
Volume 19, Issue 4 , Pages 260-267 , August 2010

Article Tools

* Image Usage & Resolution